Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OncoMed Loses Another Asset – Rosmantuzumab – And CEO Paul Hastings

Executive Summary

Loss of anti-RSPO-3 antibody rosmantuzumab, partnered with Celgene, means a rough start to the year, following disappointments in 2017.

Advertisement

Related Content

Mereo Makes It Stateside With OncoMed Merger
Deal Watch: Takeda Teams With Molecular Templates On Anti-CD38 Approach To Multiple Myeloma
Deal Watch: As J.P. Morgan Waits For New Deals, Sanofi Takes Care Of Old Business
Finance Watch: OncoMed Cuts Costs To Conserve Capital While Public, Private Peers Raise Cash
Celgene pays $177 million for cancer stem cell pact with OncoMed

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100157

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel